
Research results from RX3™ Immune Support Technology performance studies

A tale of two calves

Performance and health data summary

- · 28-35 days (30-day avg.)
- · 6 performance studies completed over 4+ years
- · 1 immune challenge study conducted
- · 500+ head of cattle observed
- · 2,900+ body weights collected
- · 3,100+ blood samples taken



Control calves³ (n=245)

Average morbidity rate



13.6%

Calves fed starters with RX3™ Immune Support Technology⁴ (n=247)



Total # of head that received respiratory treatment





16

Average

increase

Total respiratory treatment cost^⁵



\$718



\$394

Feed:Gain⁶



4.7:1



4.47:1

Effect of respiratory treatment on average daily gain

Regardless of diet fed, calves that received respiratory treatment gained less over the 30-day feeding period





3.15 lbs./day

Calves without respiratory treatment

Increase over the 30-day receiving period.

² Summary of Purina studies CG131, CG153, CG165 CG171 and PMI studies at University of Minnesota and North Dakota State University.

³ Performance data averages across all control calves

Performance data averages across all RX3™ calves.
Encompasses all costs associated with respiratory treatment.

⁶ Average dry matter intake was similar in control (15.2 lbs./day) and RX3™ (15.5 lbs./day) treatment groups.